Pembrolizumab in men with heavily treated metastatic castrate-resistant prostate cancer.
Matthew D TuckerJason ZhuDaniele MarinRajan T GuptaSantosh GuptaWilliam R BerrySundhar RamalingamTian ZhangMichael HarrisonYuan WuPatrick HealyStacey LisiDaniel J GeorgeAndrew J ArmstrongPublished in: Cancer medicine (2019)
In a heavily pretreated population of men with mCRPC, pembrolizumab was associated with a ≥50% PSA decline in 17% (8/48) of men, including a dramatic ≥90% PSA response in 8% (4/48), two of whom harbored pathogenic LRP1b mutations suggesting that LRP1b mutations may enrich for PD-1 inhibitor responsiveness in prostate cancer.